Results 71 to 80 of about 24,660,605 (261)
International Comparisons of R&D Expenditure: Does an R&D PPP Make a Difference? [PDF]
Purchasing power parities (PPPs) for R&D expenditure in 19 manufacturing industries are developed for France, Germany, Japan, the Netherlands and the United Kingdom relative to the United States for the years 1997 and 1987.
Robert H. McGuckin +3 more
core
Nonlinearity in the relationship between COVID-19 cases and carbon damages: controlling financial development, green energy, and R&D expenditures for shared prosperity. [PDF]
Environ Sci Pollut Res Int, 2022 Anser MK +9 more
europepmc +1 more source
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Background Establishing a comprehensive apheresis medicine program in a resource‐constrained setting presents significant structural, financial, and logistical challenges. Despite the growing clinical importance of apheresis services globally, published experience from sub‐Saharan Africa remains sparse.
Folasade Adelekan‐Popoola +4 more
wiley +1 more source
From campus to boardroom: CEO education and its influence on corporate policies
Financial InnovationUnlike the previous literature, this study develops a comprehensive index of CEO education that considers levels and quality in bachelor’s, master’s, and doctoral (PhD) programs and examines how they relate to corporate policies such as capital ...
Mohamad Husam Helmi +2 more
doaj +1 more source
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Background Maintenance hemodialysis (MHD) patients frequently suffer from frailty, characterized by reduced physical function and poor prognosis. Myokines, such as myonectin, secreted by muscle, are emerging regulators of systemic health. This study investigated the relationship between serum myonectin, adipokines (adiponectin, omentin), and ...
Kenichi Kono +7 more
wiley +1 more source
Determinants of R&D Expenditures and Expectations
, 1990 This study investigated the impact of individual, organizational and environmental factors on: (a) expectations of future success in research and development (R&D); and (b) changes in expenditures for R&D activities. Data was collected from executives in
Inderrieden, Edward J. +2 more
core
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Background Chronic micro‐inflammation in patients with end‐stage renal disease (ESRD) is a significant driver of cardiovascular complications and diminished quality of life. While standard hemodialysis (SHD) effectively manages small‐molecule clearance, its ability to remove medium‐to‐large uremic toxins—the primary catalysts of systemic ...
Hongwei Zuo +5 more
wiley +1 more source
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Background Japan has one of the highest dialysis prevalence rates worldwide and a shrinking, aging population. Whether dialysis burden has entered a sustained post‐peak phase or whether recent declines partly reflect pandemic‐related disruptions remains uncertain.
Hatice Şahin +2 more
wiley +1 more source
R&D Activities of Flemish Companies in the Private Sector: An Analysis for the period 1998-2002 [PDF]
The second chapter of this Study analyses the results of the last two surveys (2000 and 2002). These surveys cover a period of rapid expansion of R&D-activities in the Flemish economy. The BERD has grown on average with nearly 13% yearly between 1998 and
Michele CINCERA
core
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Introduction Peritoneal dialysis (PD) is an established home‐based kidney replacement therapy (KRT), but its uptake remains low in Japan. We evaluated whether individualized education in a dedicated outpatient clinic was associated with the initiation of PD.
Yasuko Ito +7 more
wiley +1 more source